Compositions and methods related to tauopathy

US9605042B2 · kind B2 · utility

Assignee

• Regents of the University of Minnesota · US

Inventors

• Karen Hsiao Ashe · North Oaks, US
• Xiaohui Zhao · Solo Court, CN
• Michael A. Walters · Minneapolis, US
• Derek John Hook · San Diego, US
• Morgan Clotaire Paul Le Naour · Minneapolis, US

Key dates

• Filing date: Nov 23, 2015
• Grant date: Mar 28, 2017
• Expiry date: Nov 23, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/2821
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation. Generally, the screening method includes incubating a mixture of caspase-2, a labeled caspase-2 cleavage substrate, and a test compound under conditions effective to permit the caspase-2 to cleave the caspase-2 cleavage substrate, then determining whether the test compound inhibits cleavage of the substrate by caspase-2.